Thermo Fisher Scientific Inc. (TMO) Stock Analysis — Fair Value, Risk & Moat Rating
NYQ · Healthcare · Diagnostics & Research
Is Thermo Fisher Scientific Inc. a safe investment right now?
Thermo Fisher Scientific Inc.'s Altman Z-Score of 3.58 places it in the safe zone. Our fair value estimate is $505.78 (Fairly Valued). Moat rating: 3.0/5 stars.
Could Thermo Fisher Scientific Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 3.58 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives TMO's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.1225 | 1.2 | 0.15 |
| B · Retained Earnings / Total Assets | RE / TA | 0.5361 | 1.4 | 0.75 |
| C · EBIT / Total Assets | EBIT / TA | 0.0791 | 3.3 | 0.26 |
| D · Market Cap / Total Liabilities | MCap / TL | 3.3624 | 0.6 | 2.02 |
| E · Revenue / Total Assets | Rev / TA | 0.4038 | 1.0 | 0.4 |
How has TMO's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 3.62 | Safe |
| 2023 | 3.7 | Safe |
| 2024 | 4.0 | Safe |
| 2025 | 3.58 | Safe |
Source: Calculated from TMO's latest 10-K filing on SEC EDGAR.
What is Thermo Fisher Scientific Inc. actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $20.56 | Proprietary blend of reported actuals + analyst consensus, weighted by α |
| Last Year EPS | $17.74 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $24.80 | 24 analysts consensus |
| Trailing P/E | 29.0x | Current market pricing |
| Fair P/E (β discount) | 24.6x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Accelerating | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $647.38 (24 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Thermo Fisher Scientific Inc. have a durable competitive advantage?
Moat rating: 3.0/5.
What makes up TMO's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 3/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is TMO's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 10.9% | — |
| 2023 | 9.4% | Declining |
| 2024 | 10.4% | Rising |
| 2025 | 9.4% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is Thermo Fisher Scientific Inc.'s dividend safe?
Can Thermo Fisher Scientific Inc. afford its dividend?
Payout ratio is 9.7%. FCF covers the dividend 15.2x. 18 consecutive years of payments.
Thermo Fisher Scientific Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $44.6B | $42.9B | $44.9B | Stable |
| Net Income | $6.7B | $6.3B | $7.0B | Stable |
| Free Cash Flow | $6.3B | $7.3B | $6.9B | Declining |
| Gross Margin | 40.9% | 41.3% | 42.2% | Stable |
Recent events that affect our TMO analysis
TMO earnings report scheduled
Upcoming report. Consensus EPS estimate: $5.24. Revenue estimate: $10.86B. Our current Fair Value: $505.78 — a significant beat or miss could shift this estimate.
TMO analyst consensus: 92% bullish (24 of 26 analysts)
5 Strong Buy, 19 Buy, 2 Hold, 0 Sell, 0 Strong Sell. Consensus target: $647.38 (26.0% upside). Compare with our independent Fair Value: $505.78.
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO paid $0.4700/share dividend
Dividend Safety Grade: A. Payout ratio: 9.7%.
TMO filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO beat EPS estimates by 1.9%
Reported EPS: $6.57 vs estimate $6.45. Earnings strength supports our Fair Value of $505.78 (1.6% below current price).
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO paid $0.4300/share dividend
Dividend Safety Grade: A. Payout ratio: 9.7%.
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO beat EPS estimates by 5.3%
Reported EPS: $5.79 vs estimate $5.50. Earnings strength supports our Fair Value of $505.78 (1.6% below current price).
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO paid $0.4300/share dividend
Dividend Safety Grade: A. Payout ratio: 9.7%.
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
TMO beat EPS estimates by 2.5%
Reported EPS: $5.36 vs estimate $5.23. Earnings strength supports our Fair Value of $505.78 (1.6% below current price).
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO paid $0.4300/share dividend
Dividend Safety Grade: A. Payout ratio: 9.7%.
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
TMO beat EPS estimates by 0.9%
Reported EPS: $5.15 vs estimate $5.10. Earnings strength supports our Fair Value of $505.78 (1.6% below current price).
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO paid $0.4300/share dividend
Dividend Safety Grade: A. Payout ratio: 9.7%.
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
TMO beat EPS estimates by 2.7%
Reported EPS: $6.10 vs estimate $5.94. Earnings strength supports our Fair Value of $505.78 (1.6% below current price).
TMO filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Thermo Fisher Scientific Inc.
What is Thermo Fisher Scientific Inc. stock price today?
Thermo Fisher Scientific Inc. (TMO) stock price is $513.98 as of the latest market close, traded on the NYSE exchange.
What does Thermo Fisher Scientific Inc. do?
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
What is Thermo Fisher Scientific Inc. market cap?
Thermo Fisher Scientific Inc. has a market capitalization of $191.01B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is TMO in?
Thermo Fisher Scientific Inc. operates in the Healthcare sector, specifically within the Diagnostics & Research industry. It trades on the NYSE under the ticker symbol TMO.
Is TMO stock overvalued or undervalued?
Based on our valuation model, Thermo Fisher Scientific Inc. trades 1.6% above our fair value estimate — potentially overvalued.
- FairValueLabs Fair Value: $505.78
- Current Price: $513.98
- Valuation Zone: Fairly Valued
What is TMO stock forecast and analyst target price?
Based on 24 Wall Street analysts, the consensus price target for Thermo Fisher Scientific Inc. is $647.38, implying upside of 26.0% from the current price.
- Analyst High Target: $750.00
- Analyst Low Target: $520.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Thermo Fisher Scientific Inc. revenue and earnings growing?
Here are the analyst consensus growth estimates for Thermo Fisher Scientific Inc.:
- Revenue growth (current year est.): 7.1%
- EPS growth (current year est.): 8.4%
- Revenue growth (next year est.): 5.9%
- EPS growth (next year est.): 9.5%
What are Thermo Fisher Scientific Inc.'s key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $44.6B | Stable |
| Net Income | $6.7B | Stable |
| Free Cash Flow | $6.3B | Declining |
| Gross Margin | 40.9% | Stable |
What is TMO's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 29.0x
- Forward P/E (next 12 months est.): 18.9x
- FairValueLabs Fair P/E: 24.6x
How volatile is TMO stock?
Thermo Fisher Scientific Inc. has a beta of 0.97, meaning it is roughly in line with overall market volatility. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Thermo Fisher Scientific Inc. have?
Thermo Fisher Scientific Inc.'s balance sheet shows:
- Total Cash: $10.10B
- Total Debt: $41.36B
- Net Cash Position: $-31.25B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Thermo Fisher Scientific Inc.'s free cash flow?
Thermo Fisher Scientific Inc. generated $4.39B in trailing twelve-month free cash flow (from $7.82B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Thermo Fisher Scientific Inc. pay a dividend, and is it safe?
Yes, Thermo Fisher Scientific Inc. pays a regular dividend. Here are the key metrics:
- Dividend Yield: 0.3%
- Payout Ratio: 9.7%
- Consecutive Years Paid: 18
- 5-Year Dividend Growth: -14.7%
- FairValueLabs Safety Grade: A
Is Thermo Fisher Scientific Inc. at risk of going bankrupt?
Thermo Fisher Scientific Inc.'s Altman Z-Score is 3.58, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Thermo Fisher Scientific Inc. have a durable competitive advantage?
Thermo Fisher Scientific Inc. scores 3.0/5 stars (Narrow moat) in our moat analysis:
- ROIC Stability: 3/5
- Gross Margin Trend: 3/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is TMO's return on equity (ROE)?
Thermo Fisher Scientific Inc.'s return on equity is 13.0%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy TMO stock?
TMO shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol TMO
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is TMO a value stock or speculative?
FairValueLabs classifies Thermo Fisher Scientific Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.
Who is the CEO of Thermo Fisher Scientific Inc.?
The current CEO of Thermo Fisher Scientific Inc. is Mr. Marc N. Casper.
What is TMO's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $17.73
- Forward EPS (next 12 months est.): $27.14
- Analyst consensus EPS (this year): $24.80
- Analyst consensus EPS (next year): $27.14
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
TMO analysis methodology: How we calculate fair value, Z-Scores, and moat ratings